HGSI Related Trader Talk
-
Is Human Genome (HGSI) Getting Desperate for a Deal?
-
Human Genome (HGSI) Trades Well Above GSK Offer, Other Biotechs See Action
-
Human Genome Sciences (HGSI) Shares Surge 7% Into Close
-
Bristol-Myers's (BMY) Inhibitex (INHX) Takeover Puts Hep-C, Other Biotechs on M&A Watch
-
Human Genome (HGSI), InterMune (ITMN) See Action On Dendreon's Wild Move
-
Biotech Stocks Fall In Reponse to Dendreon (DNDN)
-
Analysts Bullish on Human Genome (HGSI) Shares as Investors Selling
-
Pre-Open Movers 3/30: (CEPH) (VRX) (BLK) Higher; (UTA) (VVTV) (ZZ) Lower
-
Biotech Stocks Could See Action On Valeant (VRX) Bid for Cephalon (CEPH): (BIIB) (JAZZ) (DNDN) (REGN) (more...)
-
Pre-Open Movers: (GMCR) (HGSI) (SBUX) Higher; (JTX) (CWTR) (PEET) Lower
-
Baird Says Buy The Open, Sell The Launch on Shares of Human Genome Sciences (HGSI)
-
Human Genome Sciences (HGSI) Pop Sharply Upon Resumption, But Strength Tapers; Stock Now Up Just 6.5%
-
Analysts Positive On Human Genome Sciences (HGSI) Ahead of March 10 PDUFA Date
-
After Trading Higher Human Genome Sciences (HGSI) Now Down 8%
-
Glaxo (GSK), Human Genome's (HGSI) Benlysta Wins Backing of FDA Advisory Panel
-
GlaxoSmithKline (GSK) Higher On Positive Data from Human Genome Benlysta
-
Human Genome (HGSI) Shares Halted Ahead of Benlysta FDA Panel Review
-
Cohen's SAC Capital 13F Highlights: New Positions in McMoRan, Regis, Raised Stakes in Genzyme, Hertz, Sprint, Lowered Stakes in Apple, Exxon Mobil
-
Human Genome Sciences (HGSI) Falls After Briefing Documents Posted
-
Frontpoint Partners Said to Be Hedge Fund In SEC Tipping Case Versus a Doctor Involved with Human Genome (HGSI) Trials
-
Wall Street Hubbub 8/2: HGSI and MJN Seen As Targets, Layoffs at Barclays?, Goldman Sachs Ticks Off New Neighbors
-
Baird Upgrades Human Genome Sciences (HGSI) to Outperform
-
Study Shows Record $65 billion Spent by U.S. Biopharmaceutical Companies in R&D
-
Biotech Rumor Mill Hopping After Hostile Bid for OSI Pharmaceuticals (OSIP)
-
Human Genome Sciences (HGSI) To Offer Up to 12.5M Shares
-
Active equity option families in first 30 minutes of trading: HGSI, BAC, F, C
-
Panel Says Human Genome's (HGSI) Raxibacumab Needs More Testing
-
Headlines from Bloomberg, FDA says Human Genome Sciences (HGSI) anthrax treatment may not work
-
Human Genome Sciences (HGSI) CEO Said Lupus Drug Could Sell for $20,000/Yr or More
-
Human Genome (HGSI) Shares Spike as GlaxoSmithKline (GSK) Rumored to Have $30/Share Bid Ready
-
Human Genome Sciences (HGSI): Upgraded to Buy at ThinkEquity; target raised to $26 (new Street high)
-
Human Genome (HGSI) Shares Moving Higher Again...New Gov't Contract Announced
-
ZymoGenetics (ZGEN), Immunomedics (IMMU) Shares Rise on Positive BENLYSTA Data
-
WHO Chief: Safe Swine Flu Vaccine Still 'Several Month's Away (NVAX, BCRX, HEB, more)
-
Jim Cramer Comments on AAPL, PCU, AA & HGSI
-
Most active equity option families in first 30-minutes of Trading: BK PD MSFT AAPL TOL RIG DELL HGSI UTX
-
HGSI To Spin-Off its CoGenesys division
Back to HGSI Stock Lookup
